secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2023-06-29T23:59:59+00:00
Accession:  0001193125-23-178328
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.03, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase Therapeutics announces 1-for-6 reverse stock split to regain Nasdaq compliance
--------------------------------------------------------------------------------

- Reverse stock split effective June 30, 2023; shares outstanding reduced from ~31.6M to ~5.3M.
- Stockholder approval obtained on June 23, 2023; no fractional shares issued, fractional holders get full share.
- CUSIP changed to 45719W205; trading symbol remains 'IKT'.
- Proportional adjustments made to stock options and warrants exercise prices and shares.
- Split intended to meet Nasdaq minimum bid price requirement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312523178328/0001193125-23-178328-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312523178328/d517782d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-178328

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer